SlowBull
The Business Brief TUESDAY, 1 SEPTEMBER 2026
← All stories
Markets

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

1 source ·1 article ·3h ago Avis Budget Novartis

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·3h ago

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.